Puslapis 1 nuo 30 rezultatus
Thanks to a better understanding of the pathophysiological mechanisms of inflammatory rheumatism, rheumatology has known for several decades a growth in its therapeutic arsenal (csDMARDs, bDMARDs, tDMARDs). rheumatism control has thus been optimized.
however, patients very often keep pain, anxiety,
Despite the widespread use and availability of cannabis products, substantive deficiencies remain regarding the potential risks for cannabis or cannabinoids to precipitate adverse interactions with conventional drugs. Evidence from the few systematic clinical studies that have been conducted
People with both psychosis and cannabis abuse are particularly difficult to treat because cannabis abuse worsens psychotic symptoms and increases the risk that a first-episode psychosis will progress into schizophrenia. It is the THC (tetrahydrocannabinol) content in cannabis that aggravates
In Canada, legalization of recreational use is likely to have decreased the perception of risks associated with Cannabis use, and means that the reported adverse effects of Cannabis are not so important, suggesting that Cannabis may be useful for their illness as an alternative or complementary
Although the state-level legalization of cannabis for medical use allows access for patients, its use closely resembles the dietary supplement market. In 1994, the Dietary Supplement Health and Education Act (DSHEA) was passed, allowing dietary supplements to be available to consumers without prior
This study is a preliminary examination of the feasibility, acceptability, and effectiveness of a brief, one-session intervention for a diverse sample of young adults who report alcohol binge drinking or marijuana use in the past month. The proposed study will utilize a two-group pilot randomized
This is a 6-week randomized, double-blind, placebo-controlled, parallel group design trial followed by an open-label extension phase of 12 weeks, to evaluate tolerability of medical cannabis oil to reduce chronic pain intensity.
Consecutive adult patients between the ages of 18 and 75, male and
An estimated 8.4 million adults in the U.S. experience co-occurring psychiatric and SUDs, largely accounted for by comorbid mood disorder-SUD. Cannabis is the most widely used illicit substance among individuals with depressive disorders1. Likewise, elevated rates of major depression are observed
BACKGROUND AND RATIONALE Pain is a common symptom in PD and is reported in up to 50 % of patients. Pain in PD has been classified as musculoskeletal, dystonic (particularly in OFF-periods), radicular and central pain, and is frequently associated with muscle rigidity, postural abnormalities and
This project aims to develop and evaluate a behavioral intervention for adolescent cannabis use disorder that emphasizes adaptive responding to negative affective symptoms (e.g., depression, anxiety). Maladaptive cognitive, behavioral, and emotional reactions to negative affect are associated with
This is a 6-week randomized, double-blind, placebo-controlled, parallel group design trial followed by an open-label extension phase of 12 weeks, to evaluate the safety and efficacy of different formulations of medical cannabis oil to reduce chronic pain intensity.
The study will be conducted at